GlobeNewswire

NovAtel® Demonstrates Precise Positioning Using the Teseo APP and Teseo V Automotive GNSS Chipsets from STMicroelectronics

Dela

Deutsche Version: www.novatel.com/TeseoPRGerman

Calgary, Canada, March 06, 2018 (GLOBE NEWSWIRE) -- NovAtel, part of Hexagon's Positioning Intelligence Division, has integrated its high-precision positioning engine and correction services with the world's first automotive-grade multi-frequency GNSS chipsets, the STMicroelectronics Teseo APP (Automotive Precise Positioning) and Teseo V. The integration demonstrates future possibilities with regard to vehicle localization solutions. STMicroelectronics's Teseo APP and Teseo V provide multi-frequency GNSS data for PPP (Precise Point Positioning) and RTK (Real Time Kinematic) for accurate positioning capabilities. The Teseo APP features built-in integrity checking for use in safety-critical systems, whereas Teseo V is used for non-safety-critical precise positioning applications. NovAtel's positioning engine combines the GNSS measurements from these chipsets with Inertial Measurement Unit (IMU) data and Hexagon Precise Point Positioning (PPP) correction services on the demonstration platform to deliver centimeter-level PPP positioning solutions in real-time. 

"Working closely with STMicroelectronics using their Teseo APP chipset allowed us to innovate and speed up the development of our assured positioning solution tailored specifically for safe positioning of autonomous vehicles," said Jonathan Auld, VP Engineering and Safety Critical Systems from NovAtel.

NovAtel's positioning engine architecture enables a flexible integration with different GNSS receiver chipsets, IMUs, and processor environments, providing automotive manufacturers with additional flexibility when it comes to selecting components and subsystems of Advanced Driver Assistance Systems (ADAS) and autonomous driving solutions. The positioning engine is being developed to ASIL-B standards according to ISO26262 and will include a proprietary GNSS integrity solution to ensure safe positioning within defined protection limits that are tailored to the customer's application requirements. 

"NovAtel's choice of the automotive-quality ASIL-capable Teseo APP to integrate with their GNSS positioning engine is enabling them to develop a world-class safety-critical positioning offering to the automotive industry," said Antonio Radaelli, Director, Infotainment Business Unit, STMicroelectronics.

NovAtel technology continues to be an integral part of the connected and autonomous car ecosystems, including academic research, industry development, and real-life applications. Our automotive positioning solution includes automotive GNSS antenna technology, GNSS/INS positioning engine, and global correction services. Developed by the industry's most experienced team of high-performance, safety-critical GNSS/INS engineers.

Early results from the Teseo V demonstration platform are available now. To learn more, visit:

www.novatel.com/teseo-integration  

###

About NovAtel 

NovAtel designs, manufactures and sells high precision OEM positioning technology. Developed for efficient and rapid integration, our products have set the standard in quality and performance for over 25 years. State-of-the-art, lean manufacturing facilities in our North American headquarters produce the industry's most extensive line of OEM receivers, antennas and subsystems. All of our products are backed by a team of highly skilled application engineers.

NovAtel Inc. is part of Hexagon (Nasdaq Stockholm: HEXA B; hexagon.com), a leading global provider of information technology solutions that drive productivity and quality across geospatial and industrial landscapes.

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/978fa92c-fd66-4a77-9d7c-aeef5becdae7

http://www.globenewswire.com/NewsRoom/AttachmentNg/78e0fc9d-f134-4432-96bd-8b203dd3c5d2

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/3db4147f-f366-4cc3-b772-66832f7c36df

Jennifer Abrahams, Marketing Manager
NovAtel
1.403.630.0382
jennifer.abrahams@hexagon.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: NovAtel via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development delays publication of its Annual Report for 2018 and changes date for the Annual General Meeting26.4.2019 08:00:00 CESTPressmeddelande

STOCKHOLM, SWEDEN - 26 April 2019. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that The Board of Directors has decided to delay the publication of its Annual Report for 2018. Karolinska Development has changed the date for the Annual General Meeting to June 26, 2019. The date for publication of the Annual Report for 2018 has been changed from April 26 to April 30, 2019. Karolinska Development has changed the date for the Annual General Meeting from June 4 to June 26, 2019. Notice to the Annual General Meeting will be published in a separate press release. For more information, please contact: Viktor Drvota, CEO, Karolinska Development AB Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com Fredrik Järrsten, CFO, Karolinska Development AB Phone: +46 70 496 46 28, e-mail: fredrik.jarrsten@karolinskadevelopment.com TO THE EDITORS About Karolinska Development AB Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investmen

Karolinska Development senarelägger publicering av årsredovisningen för 2018 och meddelar nytt datum för årsstämma26.4.2019 08:00:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 26 april 2019. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att styrelsen har beslutat att senarelägga publiceringen av årsredovisningen för 2018. Karolinska Development har ändrat datum för årsstämman till den 26 juni 2019. Publiceringen av årsredovisningen för 2018 flyttas från den 26 april till den 30 april 2019. Karolinska Development har ändrat datum för årsstämman från den 4 juni till den 26 juni 2019. Kallelse till årsstämman kommer att publiceras senare i ett separat pressmeddelande. För ytterligare information, vänligen kontakta: Viktor Drvota, vd, Karolinska Development AB Tel: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com Fredrik Järrsten, finanschef, Karolinska Development AB Tel: +46 70 496 46 28, e-mail: fredrik.jarrsten@karolinskadevelopment.com TILL REDAKTÖRERNA Om Karolinska Development AB Karolinska Development AB (Nasdaq Stockholm: KDEV) är ett nordiskt investmentbolag inom life science. Bolaget fokuserar p

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum